bs-0673R-PE [Conjugated Primary Antibody]
B7H4 Polyclonal Antibody, PE Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: B7H4

Immunogen Range: 50-100/282


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 295322

Swiss Prot: Q501W4

Source: KLH conjugated synthetic peptide derived from Rat B7H4

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation (By similarity).

Conjugation: PE

Excitation/ Emission: 496,564nm/578nm

Size: 100ul

Concentration: 1ug/ul

Applications: FCM(1:20-100)

Predicted Molecular Weight: 28


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Maskey, Ninu, et al. "Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis." Tumor Biology (2014): 1-7.Read more>>
  • Kenneth Peuker. et al. Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity. 2022 MaRead more>>
VALIDATION IMAGES